Sarepta Therapeutics has collaborative agreements with the U.S. government for the advancement of its RNA-based technologies related to the development of antiviral agents targeting hemorrhagic viruses and other real-world emerging threats to public health, including the H1N1 pandemic influenza virus and other pathogenic outbreaks.
Working in collaboration with the Transformational Medical Technologies program (TMT) of the Defense Threat Reduction Agency, a part of the U.S. Department of Defense, we have been engaged in the development of antiviral agents for Marburg and Ebola viruses. Also working in cooperation TMT, we have been involved in the development of RNA-based drug candidates targeting influenza viruses, including the pandemic H1N1 influenza virus.
Sarepta has received funding from the U.S. government for a variety of other programs including Junín virus, Dengue virus, anthrax and ricin.
About Defense Threat Reduction Agency
The Defense Threat Reduction Agency (DTRA) was founded in 1998 to integrate and focus the capabilities of the Department of Defense (DoD) that address the threat by weapons of mass destruction (WMD). DTRA’s mission is to safeguard the United States and its allies from chemical, biological, radiological, nuclear, and high-yield explosive WMDs by providing capabilities to reduce, eliminate, and counter the threat and mitigate its effects. DTRA combines DoD resources, expertise, and capabilities to ensure the United States remains ready and able to address present and future WMD threats. For more information on DTRA, visit www.dtra.mil.
About Transformational Medical Technologies Program
Transformational Medical Technologies (TMT) was created by the DoD to protect the Warfighter from emerging and genetically engineered biological threats by discovering and developing a wide range of medical countermeasures through enhanced medical research, development, and test and evaluation programs. The TMT Program office is matrixed from the Joint Science and Technology Office – DTRA and Joint Program Executive Office – Chemical and Biological Defense with oversight from the Office of the Secretary of Defense. For more information on TMT, visit www.TMT-cbdefense.org.
This page was last updated on June 27, 2011.